Medicinal Cannabis Industry Australia (MCIA) Publishes Position Paper On Delta 8

Cannabiz Australia has the story…

Medicinal Cannabis Industry Australia (MCIA) has sent a position paper to members on delta-8 THC products in a bid to clear up confusion about the medicine, ensure accurate labelling, and avoid it being prescribed in error.

In October 2021, growing alarm about delta-8 products in the US, and reports of it being prescribed to patients in Australia, prompted industry bodies to warn members about the potential risks associated with the cannabinoid and to raise their concerns with regulators.

As things stand, companies with delta-8 in their products do not have to declare on the label whether the product contains delta-8 or delta-9, only that it contains THC of some kind. In its position paper, MCIA encourages companies to proactively disclose this information.

Concerns have also been raised about the solvents needed to transform delta-8 from CBD and the possibility of contamination in the final product. However, advocates for the medicine have blamed poor production methods and processes used in the US recreational market for this perception.

Read more  https://www.cannabiz.com.au/mcia-issues-position-paper-on-delta-8-thc/?utm_medium=email&utm_campaign=Cannabiz%20newsletter%203222&utm_content=Cannabiz%20newsletter%203222+CID_4dd2c16664ae388b79d200d0180d18ca&utm_source=CampaignMonitor&utm_term=READ%20MORE

Primary Sponsor

 


Karma Koala Podcast

Top Marijuana Blog